Q-omics provides the consensus-scored PVALEF profile across patient tissues and cancer cell-line models. PVALEF expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PVALEF is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, PVALEF RNA expression shows 14,819 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, BLCA, and TGCT as cancer lineages where PVALEF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PVALEF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PVALEF survival associations across molecular data types. PVALEF RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PVALEF RNA expression–survival associations across cancer types. High PVALEF expression shows unfavorable associations in KIRP, UVM, THCA and DLBC, but favorable associations in LGG and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PVALEF RNA expression.
This table summarizes PVALEF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for PVALEF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PVALEF shows lower tumor expression in BRCA and higher tumor expression in BLCA, LUAD and KIRC. The BLCA box plot shows higher PVALEF RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p = .025).
This table shows molecular features associated with PVALEF in patient tissues and cancer cell lines. In patient samples, PVALEF shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PVALEF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
